Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2S496)

Drug Name

Redoxal Drug Info

Synonyms

52962-95-5; MLS000736810; NSC73735; UNII-Q0VK2156M5; N,N'-BIS(o-CARBOXYPHENYL)-o-DIANISIDINE; Q0VK2156M5; SMR000528333; 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid; Benzoic acid, 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-; 2-[4-[4-(2-carboxyanilino)-3-methoxyphenyl]-2-methoxyanilino]benzoic acid; 2-[4-[4-(2-carboxyanilino)-3-methoxy-phenyl]-2-methoxy-anilino]benzoic acid; 2-[(4-{4-[(2-carboxyphenyl)amino]-3-methoxyphenyl}-2-methoxyphenyl)amino]benzoic acid; Mini-antibody(scFv)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 72571
CAS Number: CAS 52962-95-5
TTD Drug ID: DM2S496

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[3]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[4]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[5]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[6]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[7]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[8]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[8]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[9]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[8]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[10]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[11]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[12]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[13]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[14]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[15]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[16]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[17]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[18]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Not Available	[2]
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem. 2002 Nov 1;277(44):41827-34.
2	A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002 Jun;8(6):1710-9.
3	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
4	Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
5	Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
6	Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
7	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
10	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
12	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
13	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
14	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
15	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
16	Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
17	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
18	Clinical pipeline report, company report or official report of Roche (2009).
19	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.